or Try an Advanced Search...

    Technical Analysis for VRCA - Verrica Pharmaceuticals Inc.

    Grade Last Price % Change Price Change
    C 7.95 9.05% 0.66
    VRCA closed up 9.05 percent on Monday, July 1, 2024, on 1.28 times normal volume. It ran into resistance at its 50 day moving average.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Flat Up
    Historical VRCA trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    50 DMA Resistance Bearish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 9.05%
    Older End-of-Day Signals for VRCA ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 9 hours ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 9 hours ago
    Fell Below Previous Day's Low about 9 hours ago
    Down 2 % about 9 hours ago
    Down 1% about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    VRCA Chart by TradingView
    Basic chart:

    Profile

    Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Pharmaceutical Medication Pharmaceutical Products Clinical Trial Skin Diseases Treatment Of Skin Diseases Common Warts

    Is VRCA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs
    Jul 1 Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
    Jun 28 High Insider Ownership Growth Stocks On US Exchange For June 2024
    Jun 27 Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders
    May 30 Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
    May 30 High Insider Ownership Growth Companies On US Exchange May 2024
    May 15 Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
    May 14 Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
    May 13 Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript
    May 13 Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
    See more VRCA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.4
    52 Week Low 2.86
    Average Volume 233,902
    200-Day Moving Average 5.67
    50-Day Moving Average 7.95
    20-Day Moving Average 8.01
    10-Day Moving Average 7.45
    Average True Range 0.63
    RSI (14) 51.22
    ADX 22.8
    +DI 24.01
    -DI 18.59
    Chandelier Exit (Long, 3 ATRs) 7.46
    Chandelier Exit (Short, 3 ATRs) 8.77
    Upper Bollinger Bands 9.35
    Lower Bollinger Band 6.68
    Percent B (%b) 0.48
    BandWidth 33.34
    MACD Line -0.23
    MACD Signal Line -0.15
    MACD Histogram -0.08
    Fundamentals Value
    Market Cap 334.41 Million
    Num Shares 42.1 Million
    EPS -1.08
    Price-to-Earnings (P/E) Ratio -7.36
    Price-to-Sales 72.34
    Price-to-Book 5.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.60
    Resistance 3 (R3) 9.45 8.76 9.33
    Resistance 2 (R2) 8.76 8.34 8.83 9.23
    Resistance 1 (R1) 8.35 8.08 8.56 8.50 9.14
    Pivot Point 7.66 7.66 7.76 7.73 7.66
    Support 1 (S1) 7.25 7.24 7.46 7.40 6.76
    Support 2 (S2) 6.56 6.98 6.63 6.67
    Support 3 (S3) 6.15 6.56 6.58
    Support 4 (S4) 6.30